Business Wire: latest releases

News releases provided by Business Wire Business Wire.

Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:58am

This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape.

Key Points: 
  • This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape.
  • "Acute myeloid leukaemia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Acute myeloid leukaemia pipeline landscape is provided which includes the disease overview and Acute myeloid leukaemia treatment guidelines.
  • The assessment part of the report embraces, in depth Acute myeloid leukaemia commercial assessment and clinical assessment of the pipeline products under development.

The Worldwide Partner Relationship Management Industry is Expected to Reach $180 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:54am

To reduce expenses and downtime, these enterprises prefer adopting Partner Relationship Management (PRM) solutions.

Key Points: 
  • To reduce expenses and downtime, these enterprises prefer adopting Partner Relationship Management (PRM) solutions.
  • This has led to a significant decline in the adoption of partner relationship management services.
  • The segment is expected to reach USD 35.38 billion by 2028
    The cloud deployment segment led the market and the trend is expected to continue over the forecast period.
  • The region is anticipated to reach USD 68.3 billion by 2028.

Allergic Rhinitis Epidemiology Forecast Report 2021-2030: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:50am

The "Allergic Rhinitis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergic Rhinitis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Allergic Rhinitis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Allergic Rhinitis epidemiology division provides insights about historical and current Allergic Rhinitis patient pool and forecasted trends for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Allergic Rhinitis epidemiology [segmented as Total Prevalent Cases of Allergic Rhinitis, Total Diagnosed Cases of Allergic Rhinitis, Total Age group-specific Cases of Allergic Rhinitis, Total Allergen-specific Cases of Allergic Rhinitis, and Total Treated Cases of Allergic Rhinitis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Complement 3 Glomerulopathy (C3G) Epidemiology Forecast Report 2021-2030 with Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:44am

This 'Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This 'Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,456 in 2020.
  • The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 4,112 in 2020.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Complement 3 Glomerulopathy (C3G) during the forecast period (2021-2030)?

Global Liver Cancer Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:40am

The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global liver cancer diagnostics market size is expected to reach USD 17.4 billion by 2028.
  • The rising prevalence of liver cancer and the introduction of innovative diagnosis products are propelling the market growth.
  • The most common cause of liver cancer is chronic (long-term) infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).

Global Guanylate Cyclase Activators Pipeline Market Report 2021 Featuring Novan, Radikal Therapeutics, Ironwood Pharmaceuticals, & Bayer - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:35am

This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.

Key Points: 
  • This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.
  • A detailed picture of the Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape is provided which includes the disease overview and Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators treatment guidelines.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators: Therapeutic Assessment
    This segment of the report provides insights about the different Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:31am

This "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape.

Key Points: 
  • This "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape.
  • "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines.
  • Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Blepharitis Pipeline Market Pipeline Landscape Report 2021 Featuring NicOx, Tarsus Pharmaceuticals, AxeroVision, & InSite Vision - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:28am

This "Blepharitis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape.

Key Points: 
  • This "Blepharitis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Blepharitis R&D.
  • This segment of the report provides insights about the different Blepharitis drugs segregated based on following parameters that define the scope of the report.
  • Blepharitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Postmenopausal Osteoporosis Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:23am

The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Postmenopausal osteoporosis - Pipeline Insight, 2021 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape.
  • Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis.
  • Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Outlook on the Solar Powered ATM Global Market to 2030 - Rise in Power Cut Issues in Rural Areas is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:16am

Growing demand and increase in need of continuous electricity supply technology among banks and financial institutions and rise in power cut issues in rural areas are boosting the growth of the global solar powered ATM market.

Key Points: 
  • Growing demand and increase in need of continuous electricity supply technology among banks and financial institutions and rise in power cut issues in rural areas are boosting the growth of the global solar powered ATM market.
  • In addition, rapid adoption of solar power ATM among banks across the U.S. and Canada has positively impacted the growth of the market.
  • The global solar powered ATM market is segmented on the basis of component, type, end user, and region.
  • Information about key drivers, restraints, & opportunities and their impact analysis on global solar powered ATM market trends is provided in the report.